efficacy of evidence based exposure- or EMDR-treatment for PTSD with patients with a vulnerability for psychosis. A multiple baserate pilot study.

efficacy of evidence based exposure- or EMDR-treatment for PTSD with patients with a vulnerability for psychosis. A multiple baserate pilot study. - efficacy of PTSD-treatment in patients with psychoses. A pilot study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32890

Enrollment

Registered

2009-04-09

Start date

2009-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posttraumatische stresstoornis post traumatic stress disorder psychosis traumas

Interventions

Participants will be allocated to one of two treatment conditions, which are active PTSD treatment programmes, aimed at processing of traumatic experiences, EMDR and prolonged exposure. Both treatme

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Having had one or more psychotic episodes due to psychiatric illness (SCID-1; structured clinical interview for DSM-IV-diagnosis) 2. PTSD (CAPS: clinician-administered PTSD scale, originally by Blake, Weathers, Nagy, Kaloupek, Charney, & Keane, 1995)

Exclusion criteria

Exclusion criteria: 1. Severe dissociative disorders. High-scores on the SDQ-20 (scores above 35) are excluded because of the severe possibility of having a serious dissociative disorder. (somatoform-dissociation questionairre, 20 items; Nijenhuis, Spinhoven, Van Dyck, Van der Hart, & Vanderlinden, 1996), 2. Severe psychosis at the time of investigation (SCID-1)

Design outcomes

Secondary

Measure	Time frame
1. Style of reasoning in psychotic patients, measured by the O-Life (mason, 1995;2006). 2. Level of functioning, measured by the Outcome Questionnaire (OQ; lambert & Burlinganme, 2001). 3. Social functioning, measured by the Social Functioning Scale (van Birchwood, 1990. 4. Medication; changes 5. Number of admissions or crises during treatment	—

Primary

Measure	Time frame
• PTSD symptoms •The frequency of PTSD-symptoms will be assessed with Posttraumatic Stress Symptom Scale, Self Report, PSS- SR; Foa et al.,1993; Dutch translation; Engelhard & Arntz, 2005; Questionnaire, 17 items). • Psychotic symptoms •Psychotic symptoms will be measured by the PSYRATS (Haddocok et al., 1994, vert de Hert et al., 1996), which measures the frequency and influence of hallucinations and delusions.	—

Measure

Time frame

• PTSD symptoms •The frequency of PTSD-symptoms will be assessed with Posttraumatic Stress Symptom Scale, Self Report, PSS- SR; Foa et al.,1993; Dutch translation; Engelhard & Arntz, 2005; Questionnaire, 17 items). • Psychotic symptoms •Psychotic symptoms will be measured by the PSYRATS (Haddocok et al., 1994, vert de Hert et al., 1996), which measures the frequency and influence of hallucinations and delusions.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)